Plasma homocysteine levels in patients with Psoriasis

Das, Mousumi; Dawn, Indranil; Sarkar, Susmita; Das, Kapildev

doi:10.3126/ajms.v8i5.17136

Cited by 6 publications

(8 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the studies in the literature demonstrated that patients with psoriasis have plasma/serum Hcy levels significantly higher than controls [8–18]. Among them, some reported that the severity of psoriasis assessed according to psoriasis area and severity index (PASI) directly correlate with plasma/serum Hcy levels [10,15,17,18].…”

Section: Hcy Levels In Patients With Psoriasismentioning

confidence: 99%

Homocysteine and psoriasis

Lin

Meng²,

Song

2019

Bioscience Reports

View full text Add to dashboard Cite

Psoriasis is caused by a complex interplay among the immune system, genetic background, autoantigens, and environmental factors. Recent studies have demonstrated that patients with psoriasis have a significantly higher serum homocysteine (Hcy) level and a higher prevalence of hyperhomocysteinaemia (HHcy). Insufficiency of folic acid and vitamin B12 can be a cause of HHcy in psoriasis. Hcy may promote the immuno-inflammatory process in the pathogenesis of psoriasis by activating Th1 and Th17 cells and neutrophils, while suppressing regulatory T cells. Moreover, Hcy can drive the immuno-inflammatory process by enhancing the production of the pro-inflammatory cytokines in related to psoriasis. Hcy can induce nuclear factor kappa B activation, which is critical in the immunopathogenesis of psoriasis. There may be a link between the oxidative stress state in psoriasis and the effect of HHcy. Hydrogen sulfide (H2S) may play a protective role in the pathogenesis of psoriasis and the deficiency of H2S in psoriasis may be caused by HHcy. As the role of Hcy in the pathogenesis of psoriasis is most likely established, Hcy can be a potential therapeutic target for the treatment of psoriasis. Systemic folinate calcium, a folic acid derivative, and topical vitamin B12 have found to be effective in treating psoriasis.

show abstract

Section: Hcy Levels In Patients With Psoriasismentioning

confidence: 99%

Homocysteine and psoriasis

Lin

Meng²,

Song

2019

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…Mean PASI score was 9.16±3.91, ranging from 2.10 to 15.2. ere is no evidence of direct correlation between current disease severity and serum homocysteine levels O A Psoriasis is considered to be an independent risk factor for cardiovascular morbidity and mortality, but the exact underlying mechanisms have not yet been uncovered [3][4][5] . Some recent studies suggested that elevated serum homocysteine levels in psoriatic patients might contribute to the cardiovascular risk in psoriatic patients, due to their atherogenic and prothrombotic e ect [11][12][13][14][15] .…”

Section: Discussionmentioning

confidence: 99%

“…Homocysteine is sulfur containing amino acid, displaying atherogenic and prothrombotic features. It is produced in the metabolism of the essential amino acid methionine and can be catabolized by re-methylation to methionine in the presence of co-factors folic acid and vitamin B12 or by trans-sulfuration to cysteine in the presence of cofactor vitamin B6 8,[11][12][13][14][15] . Moreover, homocysteine promotes endothelial dysfunction and, consequently, atherosclerosis by reducing the bioavailability of nitric oxide due to inhibition of nitric oxide synthase (eNOS) and oxidative stress, provokes endothelial cell damage, and leads to a state of chronic in ammation of the endothelium 12,16 .…”

mentioning

confidence: 99%

Serum levels of homocysteine in young psoriasis patients naïve for conventional systemic and biologic therapy

Levak¹,

Plužarić²,

Krajina³

et al. 2020

Rad Hrvatske akademije znanosti i umjetnosti

View full text Add to dashboard Cite

Introduction: Psoriasis is an immune-mediated chronic in ammatory disease, a ecting approximately 1-3% of the population worldwide. Psoriasis patients are more likely to be diagnosed with cardiovascular diseases and hyperhomocysteinemia; however, it remains elusive weather serum homocysteine levels correlate to disease activity and duration of disease. e aim of this study was to investigate serum levels of homocysteine in young patients with plaque psoriasis naïve for conventional systemic and biologic therapy. An additional aim was to determine correlation of homocysteine levels with disease severity, in ammation, folic acid and vitamin B12 supplies. Materials and methods: 26 subjects were enrolled to participate in this case-control study, including 13 adult psoriatic patients naïve for systemic therapy, without comorbidities, malignancies and infectious diseases, and 13 healthy unrelated, age and sex-matched volunteers. e disease severity and life quality were assessed using standardized tools -Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), respectively. Venous blood was collected and processed for analysis of di erential blood count (DBC), erythrocyte sedimentation rate (ESR), C reactive protein (hsCRP), serum levels of homocysteine, vitamin B12 and folic acid in the routine clinical laboratory. Results Studied cohort consisted of young participants with average age around 35 years. According to the PASI index, disease severity ranged from mild (2.10) to moderate (15.2). ere was no signi cant di erence in hsCRP and DBC levels between the groups. Psoriasis patients had signi cantly higher levels of homocysteine compared to healthy subjects, but there was no evidence of hyperhomocysteinemia related to psoriasis. All subjects had normal serum levels of vitamin B12 and folic acid. A moderate negative correlation was found between plasma homocysteine level and vitamin B12 and folic acid. Furthermore, homocysteine levels did not correlate to hsCRP, total leukocytes, and thrombocytes count, but did signi cantly positively correlate to ESR. Conclusions: e risk of cardiovascular diseases should be considered among all psoriasis patients, regardless of age and disease severity, but larger prospective controlled studies are needed to estimate the role of homocysteine in cardiovascular morbidity and mortality in psoriatic patients. psoriasis, homocysteine, folic acid, cardiovascular disease

show abstract

“…Other studies have suggested that hyperhomocysteinaemia might account for the increased susceptibility to CVD in patients with psoriasis (5) . Furthermore, cardiovascular risk factors, such as dyslipidaemia, hypertension, oxidative stress, diabetes mellitus and metabolic syndrome are more prevalent among patients with psoriasis (6) .…”

Section: Introductionmentioning

confidence: 99%

Serum Homocysteine, Folic Acid and Vitamin B12 Levels in Patients with Psoriasis Vulgaris

Sharaf¹,

Ghanem²,

Marzouk

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Psoriasis is a chronic inflammatory skin condition with increased risk of cardiovascular disease. Hyperhomocysteinaemia might account for the increased susceptibility to CV diseases in psoriasis patients. Homocysteine metabolism is dependent in part on folate and vitamin B12 so deficiency of these vitamins may lead to hyperhomocysteinaemia.Objective: This study aimed to investigate the association between homocysteine, folic acid and vitamin B12 levels and psoriasis vulgaris and to evaluate the correlation between homocysteine, folic acid and vitamin B12 levels and the severity of psoriasis vulgaris. Patients and methods: This case control study included 80 subjects who were distributed into two groups; Cases group (Group A): included 50 patients with chronic plaque psoriasis vulgaris, and Control group (Group B): included 30 non psoriatic healthy, age and sex matched, subjects. Results:The mean folic acid level in the psoriasis group was 3.69 (SD 0.96) nmol/l which was statistically significantly lower as compared with the control group (5.67 ± 1.31 nmol/l) (p< 0.001). The mean vitamin B12 level in the psoriasis group was 186.94 (SD 64.90) pmol/l which was statistically significantly lower as compared with the control group (353.73 ± 76.76 pmol/l) (p<0.001). The mean homocysteine level in the psoriasis group was 18.54 (SD 4.18) nmol/mL which was statistically significantly higher as compared with the control group (11.09 ± 1.78 nmol/mL) (p<0.001). Conclusion: hyperhomocysteinaemia, decreased serum folate levels, and decreased serum B12 levels are common in patients with psoriasis. Serum homocysteine level was negatively correlated with serum folate level. No significant correlation was found between psoriasis severity (as measured by psoriasis area and severity index) and serum levels of homocysteine, folic acid, or vitamin B12.

show abstract

Plasma homocysteine levels in patients with Psoriasis

Cited by 6 publications

References 9 publications

Homocysteine and psoriasis

Homocysteine and psoriasis

Serum levels of homocysteine in young psoriasis patients naïve for conventional systemic and biologic therapy

Serum Homocysteine, Folic Acid and Vitamin B12 Levels in Patients with Psoriasis Vulgaris

Contact Info

Product

Resources

About